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Abstract
Background:  Gastrointestinal stromal tumours (GIST) frequently occur in patients with
neurofibromatosis type 1 (NF-1). It has been reported that GIST may co-exist with pancreatic
endocrine tumors but this has only been in association with NF-1.
Case presentation: A 76 year old woman presented with a 12 month history of hypoglycaemia
symptoms. Abdominal CT scan demonstrated a 13 mm insulinoma localized in the tail of her
pancreas. She was commenced on diazoxide and later underwent surgery for enucleation of
insulinoma when a small (< 1 cm) incidental tumour was discovered on her stomach wall which was
identified as GIST.
Conclusion: This is the first case report of a pancreatic insulinoma co-existing with a GIST in a
patient without NF-1. In addition, we make the first report of rapidly growing cystic GIST
recurrence following resection of a primary GIST tumour.
Background
Gastro-entero-pancreatic (GEP NE) tumours have an inci-
dence of around 30/million/population/year [1]. Pancre-
atic islet cell tumours including insulinomas represent the
2nd most common type of GEP NE tumour after carcinoid
tumour [2].
GIST most commonly occur sporadically, but show
increased tendency in patients with NF1 [3,4]. A small
number of pancreatic neuroendocrine tumors have been
described in NF-1 patients [5,6]. There have been only
nine reports of GIST associated with GEP NE tumours but
these have all been diagnosed in patients with NF-1 [7-14]
(Table 1).
Here we report the first case of insulinoma associated with
a GIST in a patient not diagnosed with NF-1 as confirmed
by the pre-operative endocrine assessment.
Case presentation
A 76 year old woman presented with a 12 month history
of hypoglycaemia symptoms. The patient underwent a
series of tests including measurement of overnight fasting
plasma glucose, measurement of plasma levels of glucose;
insulin; and c-peptide during a hypoglycaemic episode,
measurement of urinary sulphonylurea, and radiological
imaging with a CT scan. Abdominal CT scan demon-
strated a 13 mm insulinoma localized in the tail of her
pancreas. She was commenced on diazoxide and later
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underwent surgery for enucleation of insulinoma when a
small (< 1 cm) incidental tumour was discovered on her
stomach wall. The small incidental tumour was an exo-
phytic gastric wall lesion that had not been detected pre-
operatively and revealed no suspicious features suggestive
of invasion or spread on intra-operative inspection. For
this reason the lesion was excised with diathermy off the
surface of the gastric wall, the defect being closed with
Polydioxanone suture, and no frozen sections were taken
to assess invasion/spread. Macroscopically the lesion was
completely excised. The nature of the lesion was unknown
at this time. Recovery was uncomplicated and she was dis-
charged home a week later.
The pancreatic lesion (figure 1) was composed of homo-
geneous soft tissue that had the typical red brown colour
of such lesions although paler than usually seen, meas-
ured 13 mm in diameter, and its histology showed a well
differentiated neuroendocrine tumour with nesting and
trabecular pattern. The tumour cells were regular, their
nuclei were round with vesicular chromatin and no mito-
sis was identified. Numerous psammoma bodies were
seen in tumour nests and there was abundant hyalinised
stromal reaction with no remarkable inflammation or
necrosis. Immunohistochemistry showed strong positiv-
ity with chromogranin A, synaptophysin, progesterone,
oestrogen-β and insulin markers. Very occasional cells
were stained by somatostatin antibodies whilst pancreatic
polypeptide, gastrin, amyloid and CD117 (C-kit) immu-
nostaining were negative. There was a low proliferation
index with less than 1% of tumour cells being stained by
Ki67 antibody. Also, no vascular invasion was noted. The
tumour was encapsulated and looked completely excised.
The insulinoma was classified as T1NxMx.
The gastric lesion was a 6 mm firm whitish nodule in the
upper wall of her stomach and its histology revealed an
epithelioid cell tumour. Mitotic rate was very low and no
necrosis was noted. Immunohistochemistry showed uni-
form positivity with C-kit (figure 2) and CD34 markers.
Desmin, smooth muscle actin, S100, cytokeratin and neu-
roendocrine markers were all negative. Ki67 immunos-
taining revealed very low proliferation index. We
attempted performing mutation analysis on the GIST
tumour but the DNA obtained was not of sufficiently
good quality for the assay. We were unable to comment
on the nature of the tumour margin because the GIST
lesion was excised without any adjacent gastric wall tissue.
The overall appearance was that of an epithelioid kit pos-
itive incidental GIST tumour and the lesion was incom-
pletely excised.
The patient was re-admitted 6 months later with weight
loss, anorexia and vague symptoms. She had a CT scan
which showed a 3.9 × 3.9 cm fluid attenuation mass supe-
rior to the tail of her pancreas (figure 3) displacing the
stomach anteriorly. Endoscopic ultrasound confirmed a
solid/cystic irregular mass involving the stomach wall,
and in close relation to the pancreatic tail.
Table 1: Co-existent GIST and NET in patients with NF-1
GIST Neuroendocrine tumor Reference
Small bowel Papilla of Vater [10]
Small bowel Pheochromocytoma [9]
Small bowel Papilla of Vater; domatostatinoma [12]
Small bowel Pancreatic head gastrinoma [14]
Small bowel Duodenum neuroendocrine carcinoma [7]
Small bowel Pheochromocytoma [11]
Small bowel Pheochromocytoma [8]
Small bowel Pheochromocytoma [10]
Large bowel Pheochromocytoma [10]
Gross histological appearance of insulinoma showing typical  red-brown appearance of tumour Figure 1
Gross histological appearance of insulinoma showing 
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She subsequently underwent oesophagogastroduodenos-
copy-guided endoscopic ultrasound confirming an ill-
defined mass extending into the stomach wall. Cytology
revealed groups of spindly and epithelioid cells highly
suggestive of recurrent/metastatic GIST but not indicative
of a neuroendocrine tumour (figure 4). She was managed
symptomatically, discharged and had another abdominal
CT scan 7 months later that showed that the lesion had
not significantly grown in size, but did appear to have
formed 2 well defined cystic components measuring 29 ×
28 mm, and 21 × 24 mm. Owing to the small size of the
primary GIST and the frail state of the patient, she was not
treated with Imatinib (Glivec) or offered further surgery
but has subsequently been regularly reviewed by CT scan
surveillance of the lesion and has fortunately had no evi-
dence of tumour size increase or metastases.
Discussion
The first important message in our case is that a GIST can
occur simultaneously with an insulinoma in the absence
of NF-1. The GIST tumour was only incidentally discov-
ered by the operating surgeon during enucleation of the
insulinoma in our case. The literature contains only 9
published reports of the simultaneous occurrence of GIST
and GEP NE tumour in NF-1 patients [7-12] (Table 1).
None of the reported cases of co-existent GIST and GEP
NE tumours in NF-1 patients has ever involved an insuli-
noma and in fact the only report of hypoglycaemia asso-
ciated with GIST was attributed to a rare paraneoplastic
syndrome caused by over-expression of insulin-like
growth factor II [15] in an advanced gastric GIST. It is
debatable whether or not incomplete excision of the gas-
tric GIST could have been avoided but because the gastric
GIST was only discovered incidentally, showed no suspi-
cious features on gross inspection, and the opinion of
Gastric wall GIST tumour cells were strongly positive for  CD117 (c-kit) marker (×100) Figure 2
Gastric wall GIST tumour cells were strongly posi-
tive for CD117 (c-kit) marker (×100).
CT abdomen showing cystic recurrent GIST located in the region of the pancreatic tail Figure 3
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another experienced surgeon sought during the surgical
procedure was in concordance with that of the operating
surgeon, it was decided to proceed with simple excision of
the gastric lesion with minimal dissection as was done.
The other unique message in our case is the observed
rapid recurrence of the GIST following the resection of the
primary gastric wall GIST. Small GISTs, like the initial one
in our case, are usually an incidental surgical finding,
while large tumours are usually symptomatic. In our case,
following resection of the insulinoma and the small inci-
dental gastric GIST, the GIST recurred locally with rapid
enlargement. The tumour showed marked cystic transfor-
mation probably as result of central necrosis and liquefac-
tion. The reason for the rapid recurrence of the GIST is
unclear but evidence from animal studies demonstrates
that a primary tumour can inhibit its remote metastases
via circulating angiostatin such that after primary tumour
removal, the inhibition is removed and metastases
become vascularized and grow rapidly [16]. We suspect
that in our case, the primary GIST may have had a sup-
pressive effect on satellite micro-lesions which was lost
when the GIST was resected leading to aggressive local
recurrence. An additional finding is the unique cystic
change in the recurrent GIST. Although it has been
reported that a rapidly growing primary GIST can form a
lobulated cystic mass lesion [17], such rapid cystic mass
recurrence has never been reported in the literature fol-
lowing resection of a small incidental tumour. We were
surprised by the recurrence of the GIST lesion as the initial
GIST of the gastric wall had a low mitotic rate and also a
low ki-67 index. We accept that the mechanism of the
GIST 'recurrence' may be one of four possibilities: true
recurrence of the primary gastric wall GIST, undetected
primary at initial surgery when the stomach wall GIST was
removed, residual tumour from initial surgery when the
stomach wall GIST was removed, or metastatic disease
related to the primary gastric wall GIST.
In summary, this is the first case report of a non-NF-1
patient that had a pancreatic insulinoma co-existent with
a GIST, and also, the first case report of a GIST that under-
went rapid cystic recurrence following resection of the pri-
mary GIST lesion. Unfortunately our unique case report
raises more questions than provides answers because
there are very few cases of NF-1-related concurrent GEP
NE tumours and GISTs and also very little understanding
of the prognostic implications of such concurrent
tumours. Available evidence suggests that mutations in
the NF-1 gene might be involved in the pathogenesis of
GIST in NF-1 patients [18]. However it is unknown if the
same mutation exists in NF-1 patients with co-existent
GISTs and GEP NE tumours, and more importantly, it is
unknown if there are such mutations in non-NF-1
patients with co-existent GISTs and GEP NE tumours. Our
unit routinely performs gene mutation analysis on GIST
tumours but unfortunately there is a 2% failure rate in our
mutation analysis and attempts to analyse the primary
GIST lesion in this case were unsuccessful. Completing
this mutation analysis would have greatly enhanced our
understanding of the unusual co-existence of this tumour
in the setting of a non-NF-1 patient, and, also shed more
light on its unusual pattern of recurrence.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EA conceived and designed the report, analyzed all the
reports and drafted the manuscript. SB performed surgery
on the patient and participated in designing the report.
BO performed mutation analysis on the GIST tumour and
participated in the analysis of histological specimens. BM
performed the radiological procedures on the patient and
participated in designing the report. PT analyzed and
reported on all the histological specimens in the case and
participated in designing the report. All authors read and
approved the final manuscript.
References
1. Reznek RH: CT/MRI of neuroendocrine tumours.  Cancer Imag-
ing 2006, 6:S163-S177.
EUS-guided aspiration biopsy cytology of recurrent GIST  showing clusters of atypical epithelioid and spindle cells (PAP  ×400) Figure 4
EUS-guided aspiration biopsy cytology of recurrent 
GIST showing clusters of atypical epithelioid and 
spindle cells (PAP ×400).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2009, 7:18 http://www.wjso.com/content/7/1/18
Page 5 of 5
(page number not for citation purposes)
2. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV: Genetics of
neuroendocrine and carcinoid tumours.  Endocr Relat Cancer
2003, 10:437-450.
3. Ghrist TD: Gastrointestinal involvement in neurofibromato-
sis.  Arch Intern Med 1963, 112:357-362.
4. Miettinen M, Fetsch JF, Sobin LH, Lasota J: Gastrointestinal stro-
mal tumors in patients with neurofibromatosis 1: a clinico-
pathologic and molecular genetic study of 45 cases.  Am J Surg
Pathol 2006, 30:90-96.
5. Fujisawa T, Osuga T, Maeda M, Sakamoto N, Maeda T, Sakaguchi K,
Onishi Y, Toyoda M, Maeda H, Miyamoto K, Kawaraya N, Kusumoto
C, Nishigami T: Malignant endocrine tumor of the pancreas
associated with von Recklinghausen's disease.  J Gastroenterol
2002, 37:59-67.
6. Perren A, Wiesli P, Schmid S, Montani M, Schmitt A, Schmid C, Moch
H, Komminoth P: Pancreatic endocrine tumors are a rare
manifestation of the neurofibromatosis type 1 phenotype:
molecular analysis of a malignant insulinoma in a NF-1
patient.  Am J Surg Pathol 2006, 30:1047-1051.
7. Karatzas G, Kouraklis G, Karayiannakis A, Patapis P, Givalos N,
Kaperonis E: Ampullary carcinoid and jejunal stromal tumour
associated with von Recklinghausen's disease presenting as
gastrointestinal bleeding and jaundice.  Eur J Surg Oncol 2000,
26:428-429.
8. Kramer K, Siech M, Strater J, Aschoff AJ, Henne-Bruns D: [GI hem-
orrhage with fulminant shock induced by jejunal gastrointes-
tinal stromal tumor (GIST) coincident with duodenal
neuroendocrine carcinoma (NET) + neurofibromatosis (NF)
– case report and review of the literature].  Z Gastroenterol
2005, 43:281-288.
9. Kramer K, Hasel C, Aschoff AJ, Henne-Bruns D, Wuerl P: Multiple
gastrointestinal stromal tumors and bilateral pheochromo-
cytoma in neurofibromatosis.  World J Gastroenterol 2007,
13:3384-3387.
10. Lisewski D, Ryan S, Lim EM, Frost F, Nguyen H: Concomitant com-
postite adrenal phoechromocytoma, multipte gastric stro-
mal tumours and pseudohermaphrodism in a patient with
von Recklinghausen's disease.  Int Semin Surg Oncol 2006, 3:11.
11. Rizzo S, Bonomo S, Moser A, Bottura D, Castellini C, Mazzola F,
Lauro E, Vicenzi L, Betresini B, Angeli G, Brazzarola P, D'Azzò G,
Rosa G: [Bilateral pheochromocytoma associated with duo-
deno-jejunal GIST in patient with von Recklinghausen dis-
ease: report of a clinical case].  Chir Ital 2001, 53:243-246.
12. Teramoto S, Ota T, Maniwa A, Matsui T, Itaya N, Aoyagi K, Kusanagi
H, Narita M: Two von Recklinghausen's disease cases with
pheochromocytomas and gastrointestinal stromal tumors
(GIST) in combination.  Int J Urol 2007, 14:73-74.
13. Usui M, Matsuda S, Suzuki H, Hirata K, Ogura Y, Shiraishi T: Soma-
tostatinoma of the papilla of Vater with multiple gastrointes-
tinal stromal tumors in a patient with von Recklinghausen's
disease.  J Gastroenterol 2002, 37:947-953.
14. Pagogna S, Zanini N, Tomassetti P, Casadei R, Grottola T, Ricci C,
Minni F: Neuroendocrine Tumor of the Pancreas and GIST: Is
there a Correlation?  J Pancreas (Online) 2004, 6:501-502.
15. Guiteau J, Fanucchi M, Folpe A, Staley CA III, Kooby DA: Hypoglyc-
emia in the setting of advanced gastrointestinal stromal
tumor.  Am Surg 2006, 72:1225-1230.
16. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M,
Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angio-
genesis inhibitor that mediates the suppression of metas-
tases by a Lewis lung carcinoma.  Cell 1994, 79:315-328.
17. Ding G, Yang J, Cheng S, Kai L, Nan L, Zhang S, Cong W, Wu M: A
rare case of rapid growth of exophytic gastrointestinal stro-
mal tumor of the stomach.  Dig Dis Sci 2005, 50:820-823.
18. Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pau-
wels P, De Wever I, Vermeesch JR, de Raedt T, De Paepe A, Spele-
man F, van Oosterom A, Messiaen L, Legius E: Molecular
pathogenesis of multiple gastrointestinal stromal tumors in
NF1 patients.  Hum Mol Genet 2006, 15:1015-1023.